Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Profit After Tax: 2009-2024

Historic Profit After Tax for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to -$465.9 million.

  • Madrigal Pharmaceuticals' Profit After Tax fell 6.76% to -$114.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$289.1 million, marking a year-over-year increase of 44.25%. This contributed to the annual value of -$465.9 million for FY2024, which is 24.70% down from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Profit After Tax of -$465.9 million as of FY2024, which was down 24.70% from -$373.6 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Profit After Tax ranged from a high of -$202.2 million in FY2020 and a low of -$465.9 million during FY2024.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Profit After Tax value was -$373.6 million (recorded in 2023), while the average stood at -$378.3 million.
  • Data for Madrigal Pharmaceuticals' Profit After Tax shows a maximum YoY slumped of 140.92% (in 2020) over the last 5 years.
  • Madrigal Pharmaceuticals' Profit After Tax (Yearly) stood at -$202.2 million in 2020, then dropped by 19.58% to -$241.8 million in 2021, then declined by 22.12% to -$295.4 million in 2022, then dropped by 26.50% to -$373.6 million in 2023, then declined by 24.70% to -$465.9 million in 2024.